1. Home
  2. KMDA vs GUG Comparison

KMDA vs GUG Comparison

Compare KMDA & GUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KMDA
  • GUG
  • Stock Information
  • Founded
  • KMDA 1990
  • GUG 2021
  • Country
  • KMDA Israel
  • GUG United States
  • Employees
  • KMDA N/A
  • GUG N/A
  • Industry
  • KMDA Biotechnology: Pharmaceutical Preparations
  • GUG Trusts Except Educational Religious and Charitable
  • Sector
  • KMDA Health Care
  • GUG Finance
  • Exchange
  • KMDA Nasdaq
  • GUG Nasdaq
  • Market Cap
  • KMDA 430.1M
  • GUG 470.0M
  • IPO Year
  • KMDA N/A
  • GUG N/A
  • Fundamental
  • Price
  • KMDA $7.35
  • GUG $15.64
  • Analyst Decision
  • KMDA Strong Buy
  • GUG
  • Analyst Count
  • KMDA 2
  • GUG 0
  • Target Price
  • KMDA $13.00
  • GUG N/A
  • AVG Volume (30 Days)
  • KMDA 49.4K
  • GUG 108.9K
  • Earning Date
  • KMDA 08-13-2025
  • GUG 01-01-0001
  • Dividend Yield
  • KMDA 2.72%
  • GUG 9.67%
  • EPS Growth
  • KMDA 27.97
  • GUG N/A
  • EPS
  • KMDA 0.32
  • GUG N/A
  • Revenue
  • KMDA $169,517,000.00
  • GUG N/A
  • Revenue This Year
  • KMDA $14.51
  • GUG N/A
  • Revenue Next Year
  • KMDA $9.31
  • GUG N/A
  • P/E Ratio
  • KMDA $22.26
  • GUG N/A
  • Revenue Growth
  • KMDA 9.67
  • GUG N/A
  • 52 Week Low
  • KMDA $5.17
  • GUG $12.71
  • 52 Week High
  • KMDA $9.16
  • GUG $15.06
  • Technical
  • Relative Strength Index (RSI)
  • KMDA 48.99
  • GUG 59.07
  • Support Level
  • KMDA $7.15
  • GUG $15.13
  • Resistance Level
  • KMDA $7.85
  • GUG $15.84
  • Average True Range (ATR)
  • KMDA 0.22
  • GUG 0.19
  • MACD
  • KMDA 0.00
  • GUG 0.04
  • Stochastic Oscillator
  • KMDA 54.13
  • GUG 72.34

About KMDA Kamada Ltd.

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

About GUG Guggenheim Active Allocation Fund of Beneficial Interest

Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.

Share on Social Networks: